ReviewClinical interventions in aging2021
Diabetic Retinopathy in the Aging Population: A Perspective of Pathogenesis and Treatment.
Review in Clinical interventions in aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Traditional Chinese Medicine Injections for Diabetic Retinopathy: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.Journal of integrative and complementary medicine · 2022Pooled it
- Predictors of time to diabetic retinopathy in patients with type 2 diabetes mellitus: a survival analysis study.BMC ophthalmology · 2026Article
- Exosomes in the treatment of age-related ophthalmic diseases: an updated review.International ophthalmology · 2026Review
- Factors associated with preventive behaviors for microvascular complications and self-reported neuropathy symptoms among community-dwelling individuals with type 2 diabetes in Thailand.BMC public health · 2026Article
- Review
- Retinal aging and diabetic retinopathy: converging metabolic pathways and shared gene expression profiles.Metabolic brain disease · 2026Review
- The Effect of Periodontitis Severity on Diabetic Retinopathy: An Optical Coherence Tomography Study.Diagnostics (Basel, Switzerland) · 2026Article
- Age at type 2 diabetes onset, HOMA-derived indices and risks of diabetic retinopathy: a real-world cross-sectional study.Frontiers in endocrinology · 2026Article
- Decoding Vascular Senescence: Cellular Insights and Therapeutic Strategies.International journal of biological sciences · 2026Review
- Development and Novel Therapeutics in Diabetic Retinopathy.Current diabetes reviews · 2026Review
- Prevalence and determinants of comorbidities among patients with type 2 diabetes mellitus in Nepal: a cross-sectional study.BMC endocrine disorders · 2025Article
- Deep Learning Network with Illuminant Augmentation for Diabetic Retinopathy Segmentation Using Comprehensive Anatomical Context Integration.Diagnostics (Basel, Switzerland) · 2025Article
- Prediction of advanced chronic kidney disease through retinal fundus images by deep learning.Scientific reports · 2025Article
- Exploring the Causal Relationships Between Psychiatric Disorders and Diabetic Retinopathy: A Mendelian Randomization Study.Psychiatry and clinical psychopharmacology · 2025Article
- Retinoprotective Effects of Abscisic Acid in Ischemic Retinopathy Mouse Model.Antioxidants (Basel, Switzerland) · 2025Article
- Dose-Dependent Relationship Between Long-Term Metformin Use and the Risk of Diabetic Retinopathy: A Population-Based Cohort Study.Clinical drug investigation · 2025Article
- Investigation of UCHL3 and HNMT Gene Polymorphisms in Greek Patients with Type 2 Diabetes Mellitus and Diabetic Retinopathy.Biomedicines · 2025Article
- Association between age at diagnosis of diabetes and ocular disease: Insights from a recent article.World journal of diabetes · 2025Article
- Vulnerable parafoveal microcirculation quadrant in patients with type 2 diabetes mellitus.Scientific reports · 2025Observational
- Association of long-term use of dipeptidyl peptidase-4 inhibitors with the risk of diabetic retinopathy in patients with diabetes mellitus: a real-world evidence study.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The elderly population in the United States is projected to almost double by the year 2050. In addition, the numbers of diabetics are rising, along with its most common complication, diabetic retinopathy (DR). To effectively treat DR within the elderly population, it is essential first to consider the retinal changes that occur due to aging, such as decreased blood flow, retinal thinning, and microglial changes, and understand that these changes can render the retina more vulnerable to oxidative and ischemic damage. Given these considerations, as well as the pathogenesis of DR, specific pathways could play a heightened role in DR progression in elderly patients, such as the polyol pathway and the vascular endothelial growth factor (VEGF) axis. Current ocular treatments include intravitreal corticosteroids, intravitreal anti-VEGF agents, laser photocoagulation and surgical interventions, in addition to better control of underlying diabetes with an expanding range of systemic treatments. While using therapeutics, it is also essential to consider how pharmacokinetics and pharmacodynamics change with aging; oral drug absorption can decrease, and ocular drug metabolism might affect the dosing and delivery methods. Also, elderly patients may more likely be nonadherent to their medication regimen or appointments than younger patients, and undertreatment with anti-VEGF drugs often leads to suboptimal outcomes. With a rising number of elderly DR patients, understanding how aging affects disease progression, pharmacological metabolism, and adherence are crucial to ensuring that this population receives adequate care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.